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Many tumor-specific or tumor-associated antigens 
have been discovered, but only a few of them have been 
successfully used for cancer therapy. Not only are the 
pharmacological properties of therapeutic drug molecules 
critical to the clinical success, the biological nature of 
the target antigens has a big influence on the therapeutic 
outcome. 
In searching for good drug targets for cancer, our 
lab discovered a cell surface protein called mesothelin in 
the 1990s. It is highly expressed in many tumors such as 
mesothelioma, ovarian cancer, pancreatic cancer and lung 
cancer. However, it only has minor expression in normal 
mesothelial  cells  lining  the  pleura,  pericardium  and 
peritoneum. This expression pattern makes it an attractive 
target. We designed a mesothelin targeted immunotoxin 
called SS1P in which the Fv portion of an anti-mesothelin 
antibody is fused to a truncated portion of Pseudomonas 
exotoxin A (PE38). 
The cell-killing mechanism of immunotoxin involves 
three general steps. i) The SS1P immunotoxin molecule 
binds to mesothelin on the cell surface; ii) SS1P enters the 
cell through a mesothelin-mediated internalization process 
and its PE portion is translocated to the cytosol; and iii) 
the PE molecule causes ADP-ribosylation of EF-2, leading 
to arrest of protein synthesis and apoptosis. SS1P turns out 
to be very toxic to mesothelioma cells, yet is well tolerated 
by patients in spite of low level mesothelin expression in 
normal tissue. We observed several minor responses in our 
phase I clinical trials [1]. 
Depending  on  the  cell-killing  mechanism,  the 
cytotoxicity  of  an  immunotoxin  can  be  significantly 
affected by the target properties, such as the signaling 
pathway involved, the cell surface target density, target 
internalization  rate,  target-mediated  membrane  traffic 
pathway,  etc.  Mesothelin  is  a  GPI-anchored  protein 
without an intracellular tail. Its physiological ligand has 
not been identified and it is not known if mesothelin is 
involved in any signaling pathway. Mesothelin has been 
shown to bind to another cell surface protein, MUC16. 
Mesothelin  has  several  features,  which  make  it 
useful for cancer therapy. Mesothelin is well-internalized, 
making it a good target for immunotoxins. Mesothelin is 
actively shed from the cell surface, generating an antigen 
pool in the circulation and in the tumor interstitial space. 
The measurement of serum levels of shed mesothelin 
is used as a criterion in the diagnosis of mesothelioma 
and ovarian cancer in patients. Mesothelin in the tumor 
interstitial space will inevitably interact with its targeting 
agents during the process of tumor penetration. To better 
understand the biological and pharmacological significance 
of mesothelin shedding, we studied the mechanism of 
shedding in the A431/H9 cell line, which highly expresses 
mesothelin on its cell surface [2]. Although mesothelin is 
attached to the cell membrane through its GPI anchor and 
phospholipase (PL) can release the protein, PL does not 
seem to play a significant role in the shedding because 
several PL inhibitors failed to reduce the shedding, and 
sequencing of shed mesothelin did not reveal the amino 
acid sequence expected from PL C action [2, 3]. Instead, 
we found that broad-spectrum MMP/ADAM inhibitors 
significantly inhibit mesothelin shedding. We narrowed 
down the candidate MMP/ADAM genes by testing the 
inhibitory  effect  of  several  endogenous  MMP/ADAM 
inhibitors. These studies led us to ADAM17/TACE, the 
first ‘sheddase’ to be identified, which has been implicated 
in the release of a diverse variety of membrane-anchored 
cytokines,  cell  adhesion  molecules,  receptors,  ligands 
and enzymes. TACE knockdown by siRNA significantly 
reduced mesothelin shedding. 
TACE is a transmembrane glycoprotein, most noted 
in cancer for its role in releasing EGFR ligands from the 
cell surface, by which it can regulate the activation of the 
EGFR pathway. There is evidence that chemotherapy can 
activate TACE, contributing to drug resistance, whereas 
inhibiting TACE can sensitize tumor cells to chemotherapy 
[4,  5].  We  observed  that  cytotoxicity  of  SS1P  was 
increased in cultured cells when TACE was knocked down 
by siRNA or inhibited by small inhibitor molecules. We 
do not know whether the EGFR pathway plays a role in 
this finding but we saw increased cell surface mesothelin 
levels and an increased internalization rate of SS1P. These 
are favorable characteristics for SS1P therapy. Considering 
the possibility of translating our research finding to the 
clinic, we examined other mesothelin-expressing cell lines 
and primary mesothelioma cells from several patients. 
TACE inhibition was shown to sensitize these cells to 
SS1P. We attribute this effect to the reduced dissociation 
of  targeting  molecules  bound  to  mesothelin  from  the 
cell surface after binding. Currently there is no effective 
ADAM17 inhibitor available for clinical studies. Several 
broad-spectrum MMP/ADAM inhibitors failed in clinical 
trials, so it would probably be difficult to get a protocol 
approved to directly evaluate this approach in patients. 
There is a new small molecule called INCB7839 which is 
showing some promising results [6]. 
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complicated  process.  The  modulation  of  mesothelin 
shedding could have a systemic influence on drug kinetics 
in both circulation and tumor tissue. Our in vitro assay did 
not take this into consideration, which could be essential 
when developing a therapeutic strategy. Besides shedding, 
mesothelin levels could be modulated like other antigens 
by trogocytosis [7] or antigen masking [8]. Whether they 
play a role in mesothelin targeted therapy remains to 
be evaluated. An understanding of possible mesothelin 
modulation  will  be  instrumental  to  new  targeting 
strategies.
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